CHOP-led Pediatric Hospital Network Receives Critical Government Support for Genetic Research of Pediatric Tumors
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Molecular Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
/PRNewswire/ -- Unlocking the genetic mysteries behind pediatric brain tumors is at the heart of the mission of the Center for Data Driven Discovery in...
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
Businesses can utilize Cancer Stem Cell Therapy Market 2021 research report to obtain productive ideas with which product can be made more effective and impressive in the competitive market. Market report assists in validating the information which has been gathered from the primary sources. This market document co...
E-Mail IMAGE: Dr. O'Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms... view more Credit: University of Pennsylvania The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficien...